ALNY 阿里拉姆制藥

添加自選

143.310
-0.400-0.28%

收盤價 04/26 16:00 (美東)

146.710
+3.400+2.37%

盤後 19:42 (美東)

181.22億總市值-40713市盈率TTM

關於阿里拉姆制藥公司

Alnylam Pharmaceuticals是RNA干擾(RNAi)治療研究的領導者。RNAi是細胞內一種自然發生的生物通路，用於序列特異性沉默和調控基因表達。Alnylam有5種藥物上市:Onpattro和Amvuttra治療hATTR澱粉樣變，Givlaari治療急性肝卟啉，Oxlumo治療原發性高草酸尿1型，Leqvio治療高膽固醇血癥。它也有幾個不同治療領域的臨牀項目:遺傳藥物;cardio-metabolic疾病;肝臟感染性疾病和中樞神經系統/眼部疾病。來自研究合作伙伴的預付費用提高了Alnylam的現金水平，該公司有望從合作伙伴關係下的藥物商業化中看到更多的里程碑和版稅。

公司介紹

公司代碼ALNY

公司名稱阿里拉姆制藥

上市日期2004/05/27

發行價格6.00

成立日期2002

CEODr. Yvonne L Greenstreet, MB.Ch.B.

所屬市場納斯達克

員工數量2100

證券類型海外普通股

年結日12-31

公司地址675 West Kendall Street,Henri A. Termeer Square

城市Cambridge

省份麻塞諸塞州

國家美國

郵編02142

電話1-617-551-8200

網址http://www.alnylam.com

董事高管

姓名
職務
年薪

Dr. Yvonne L Greenstreet, MB.Ch.B.
Director and Chief Executive Officer
889.57萬

Kevin Joseph Fitzgerald, PhD
Executive Vice President, Chief Scientific Officer and Head, Early Research and Early Development
--

Dr. Pushkal P. Garg, M.D.
Chief Medical Officer and Executive Vice President, Development and Medical Affairs
323.11萬

Dr. Akshay K. Vaishnaw, M.D.,PhD
Chief Innovation Officer
331.72萬

Jeffrey V. Poulton
Executive Vice President, Chief Financial Officer and Principal Accounting Officer
322.44萬

Tolga Tanguler
Chief Commercial Officer
286.97萬

Amy W. Schulman
Chairman of the Board
53.14萬

Michael W. Bonney
Director
46.72萬

Peter N. Kellogg
Independent Director
65.87萬

Dr. Dennis A. Ausiello, M.D.
Independent Director
47.72萬

David E.I. Pyott, M.B.A.,M.D.
Independent Director
47.72萬

Dr. Phillip A. Sharp,PhD
Independent Director
50.22萬

Dr. Olivier Raymond Brandicourt, M.D.
Independent Director
48.10萬

Colleen F. Reitan
Independent Director
48.92萬

Dr. Carolyn R. Bertozzi, PhD
Independent Director
66.89萬

Dr. Margaret A. Hamburg, M.D.
Independent Director
47.14萬

Dr. Elliott Sigal, M.D.,PhD
Independent Director
47.01萬

分析

分析師評級

暫無數據

目標價預測

暫無數據

熱議

美股

綜合熱度